Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information
First Received Date ^†	June 4, 2008
Last Updated Date	April 15, 2009
Start Date ^†	June 2008
Current Primary Outcome Measures ^† (submitted: June 5, 2008)	Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12 [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ] Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12 [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ^†	Same as current
Change History	Complete list of historical versions of study NCT00691964 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^† (submitted: June 5, 2008)	Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12 [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
Original Secondary Outcome Measures ^†	Same as current

Descriptive Information
Brief Title ^†	Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Official Title ^†	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary	Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
Detailed Description
Study Phase	Phase III
Study Type ^†	Interventional
Study Design ^†	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study
Condition ^†	Plaque Psoriasis
Intervention ^†	Biological: ABT-874 Biological: etanercept Drug: placebo
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^†	Completed
Enrollment ^†	347
Completion Date
Primary Completion Date	March 2009 (final data collection date for primary outcome measure)
Eligibility Criteria ^†	Inclusion Criteria: Diagnosis of Psoriasis for 6 mo. BSA 10%, PASI 12 or above, PGA 3 or above Exclusion Criteria: Previous exposure to either etanercept or ABT-874
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States
Expanded Access Status

Administrative Information
NCT ID ^†	NCT00691964
Responsible Party	Nicky Mayber, Abbott
Secondary IDs ^††
Study Sponsor ^†	Abbott
Collaborators ^††	Paragon Biomedical
Investigators ^†
Information Provided By	Abbott
Verification Date	April 2009
^† Required WHO trial registration data element. ^†† WHO trial registration data element that is required only if it exists.